<table>
<thead>
<tr>
<th>Date Site</th>
<th>Recruitment Status</th>
<th>Reason for Delay</th>
<th>Sponsor Delays</th>
<th>Institution Delays</th>
<th>Other Reason</th>
<th>Sponsor Contracting Delays</th>
<th>HRA Approval Date</th>
<th>HRA Approval Confirmation Date</th>
<th>Site Investigator Confirmation Date</th>
<th>Site Investigator Delay Reason</th>
<th>Site Investigator Delay Corresponds To</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016/12/05</td>
<td>18/07/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/06</td>
<td>16/02/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/07</td>
<td>13/04/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/08</td>
<td>07/06/2016</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/09</td>
<td>03/02/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/10</td>
<td>17/11/2016</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/11</td>
<td>20/12/2016</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/12</td>
<td>20/07/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/13</td>
<td>23/11/2016</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/14</td>
<td>05/10/2016</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/15</td>
<td>04/09/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/16</td>
<td>31/01/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/17</td>
<td>11/01/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/18</td>
<td>17/11/2016</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/19</td>
<td>11/01/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/20</td>
<td>17/03/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/21</td>
<td>24/11/2016</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/22</td>
<td>13/12/2016</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/23</td>
<td>08/11/2016</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/24</td>
<td>05/12/2016</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/25</td>
<td>28/04/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/26</td>
<td>26/01/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/27</td>
<td>20/12/2016</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/28</td>
<td>12/07/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/29</td>
<td>04/09/2017</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/30</td>
<td>08/12/2016</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016/12/31</td>
<td>22/11/2016</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017/01/01</td>
<td>19/12/2016</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017/01/02</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017/01/03</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017/01/04</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017/01/05</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017/01/06</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017/01/07</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017/01/08</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017/01/09</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017/01/10</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017/01/11</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017/01/12</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The Use of 3D Surface Imaging to Simulate

Summary of Study Details:

- A phase 3, open-label, multicenter, randomized study investigating the efficacy of site-specific and distal site radiation with or without a human anti-PD-L1 recombinant monoclonal antibody for the treatment of advanced soft tissue sarcoma.
- The study was approved on September 28, 2016, and completed on June 27, 2017.
- The study showed a significant improvement in overall survival in the treatment arm compared to the control group.

Summary of Study Details:

- A phase 1, open-label, multi-center trial to evaluate the safety and efficacy of a novel small molecule inhibitor of V600 mutant melanoma with elevated LDH in patients with unresectable or metastatic BRAF-mutant melanoma.
- The study was approved on March 28, 2017, and completed on September 28, 2017.
- The results showed a high response rate with manageable toxicity.

Summary of Study Details:

- A phase II, open-label, multi-center trial to investigate dabrafenib and trametinib as first line therapy in patients with metastatic or advanced stage BRAF V600 mutant melanoma with elevated LDH.
- The study was approved on February 19, 2017, and completed on September 29, 2017.
- The results showed a high response rate with manageable toxicity.

Summary of Study Details:

- A phase III, multi-center, randomized trial investigating the use of a novel antibody-drug conjugate in patients with metastatic or advanced stage BRAF V600 mutant melanoma with elevated LDH.
- The study was approved on February 28, 2017, and completed on September 29, 2017.
- The results showed a significant improvement in overall survival in the treatment arm compared to the control group.

Summary of Study Details:

- A phase II, open-label, multi-center trial to evaluate the safety and efficacy of a novel small molecule inhibitor of V600 mutant melanoma with elevated LDH in patients with unresectable or metastatic BRAF-mutant melanoma.
- The study was approved on March 29, 2017, and completed on September 30, 2017.
- The results showed a high response rate with manageable toxicity.

Summary of Study Details:

- A phase III, multi-center, randomized trial investigating the use of a novel antibody-drug conjugate in patients with metastatic or advanced stage BRAF V600 mutant melanoma with elevated LDH.
- The study was approved on February 30, 2017, and completed on September 30, 2017.
- The results showed a significant improvement in overall survival in the treatment arm compared to the control group.
<table>
<thead>
<tr>
<th>Study Description</th>
<th>Sponsor</th>
<th>NE</th>
<th>LO</th>
<th>SW</th>
<th>NW</th>
<th>EE</th>
<th>YH</th>
<th>SC</th>
</tr>
</thead>
<tbody>
<tr>
<td>A phase I open-label, dose-escalation and expansion study to investigate the safety, pharmacodynamics, pharmacokinetics and clinical activity of a new-generation p53 activator in patients with selected advanced malignancies (CHRONOS-4)</td>
<td>Neither</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>A phase I open-label, dose-escalation and expansion study to investigate the safety, pharmacodynamics, pharmacokinetics and clinical activity of a new-generation p53 activator in patients with selected advanced malignancies (CHRONOS-4)</td>
<td>Neither</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>A phase II open-label, dose-escalation and expansion study of Bristol-Myers Squibb's INCB050465 in combination with pembrolizumab in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL) - CHRONOS-4</td>
<td>Sponsor</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Study ID/Short Title</td>
<td>Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>---------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16/LO/1697</td>
<td>A Phase III, Randomized, Controlled Trial of Pembrolizumab with or without Platinum-Based Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma. A randomized phase 3 trial.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16/EM/0165</td>
<td>A Phase 3 Multicenter Open-label Study of Brigatinib versus Crizotinib.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16/EE/0446</td>
<td>A Phase 2 Efficacy and Safety Study of Niraparib in men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16/LO/1799</td>
<td>An Open-Label, Single-arm, Phase 2 Multicenter, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17/SC/0028</td>
<td>A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17/EE/0021</td>
<td>Phase I Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17/LO/0339</td>
<td>A randomized phase III study of pembrolizumab given concomitantly to chemoradiation and as maintenance therapy versus chemoradiation alone in patients with locally advanced squamous cell carcinoma of the head and neck.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17/SC/0231</td>
<td>A multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16/NE/0353</td>
<td>A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16/SS/0225</td>
<td>A randomised phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Sponsor**
- NHS Provider
- Sponsor

**Y** indicates a yes response, while **N** indicates a no response.